openPR Logo
Press release

Burns Pipeline 2024: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight by DelveInsight | MediWound, Kaken Pharma, Kerecis, Medline, Mallinckrodt Pharma, Avita Medical, Vericel Corporation, KeraNetics, Integra LifeSciences Corporation

02-26-2025 08:13 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Burns Pipeline 2024: Therapies, MOA Insights, and Key Clinical

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Burns pipeline constitutes 12+ key companies continuously working towards developing 12+ Burns treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Burns Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Burns Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Burns Market.

Some of the key takeaways from the Burns Pipeline Report: https://www.delveinsight.com/sample-request/burns-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Burns treatment therapies with a considerable amount of success over the years.
• Burns companies working in the treatment market are NeoMatrix Therapeutics, Inc., Topadur, Pharmaxis Ltd, Skingenix, Inc, CUTISS AG, and others, are developing therapies for the Burns treatment
• Emerging Burns therapies in the different phases of clinical trials are- NMT-cNP8, TOP-N44, PXS-6302, NMT- cP12, MW-III, DenovoSkinTM, and others are expected to have a significant impact on the Burns market in the coming years.
• In August 2024, MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, announced today that the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for NexoBrid® (anacaulase-bcdb), enabling eschar removal in pediatric patients from newborn to eighteen years old with deep partial- and/or full-thickness thermal burns. With this FDA approval, NexoBrid is now authorized for use in the U.S. across all age groups, in line with its approvals in the European Union and Japan.

Burns Overview
Burns are injuries to the skin or other tissues caused by heat, radiation, electricity, chemicals, or friction. They vary in severity from minor to life-threatening and can result in damage to the skin, underlying tissues, and even organs. Burns are classified based on their depth and extent, commonly categorized as first-degree, second-degree, third-degree, and fourth-degree burns.

Get a Free Sample PDF Report to know more about Burns Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/burns-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Burns Drugs Under Different Phases of Clinical Development Include:
• NMT-cNP8: NeoMatrix Therapeutics, Inc.
• TOP-N44: Topadur
• PXS-6302: Pharmaxis Ltd
• NMT- cP12: NeoMatrix Therapeutics, Inc
• MW-III: Skingenix, Inc
• DenovoSkinTM: CUTISS AG

Burns Route of Administration
Burns pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Burns Molecule Type
Burns Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Burns Pipeline Therapeutics Assessment
• Burns Assessment by Product Type
• Burns By Stage and Product Type
• Burns Assessment by Route of Administration
• Burns By Stage and Route of Administration
• Burns Assessment by Molecule Type
• Burns by Stage and Molecule Type

DelveInsight's Burns Report covers around products under different phases of clinical development like development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Burns product details are provided in the report. Download the Burns pipeline report to learn more about the emerging Burns therapies
https://www.delveinsight.com/sample-request/burns-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Burns Therapeutics Market include:
Key companies developing therapies for Burns are - Mallinckrodt Pharmaceuticals, Avita Medical, Vericel Corporation, KeraNetics, Integra LifeSciences Corporation, PolyNovo, MediWound Germany GmbH, Kaken Pharmaceutical Co., Ltd., Kerecis, Medline Industries, Anika Therapeutics, Inc., ACell, Inc., Amryt Pharma, CUTISS AG, Skingenix, RenovaCare, and others.

Burns Pipeline Analysis:
The Burns pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Burns with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Burns Treatment.
• Burns key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Burns Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Burns market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Burns drugs and therapies
https://www.delveinsight.com/sample-request/burns-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Burns Pipeline Market Drivers
• Rising incidence of burns, high demand of Skin grafts, growing awareness of available treatment options are some of the important factors that are fueling the Burns Market.

Burns Pipeline Market Barriers
• However, stringent regulatory approval, high cost of treatment and other factors are creating obstacles in the Burns Market growth.

Scope of Burns Pipeline Drug Insight
• Coverage: Global
• Key Burns Companies: NeoMatrix Therapeutics, Inc., Topadur, Pharmaxis Ltd, Skingenix, Inc, CUTISS AG, and others
• Key Burns Therapies: NMT-cNP8, TOP-N44, PXS-6302, NMT- cP12, MW-III, DenovoSkinTM, and others
• Burns Therapeutic Assessment: Burns current marketed and Burns emerging therapies
• Burns Market Dynamics: Burns market drivers and Burns market barriers

Request for Sample PDF Report for Burns Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/burns-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Burns Report Introduction
2. Burns Executive Summary
3. Burns Overview
4. Burns- Analytical Perspective In-depth Commercial Assessment
5. Burns Pipeline Therapeutics
6. Burns Late Stage Products (Phase II/III)
7. Burns Mid Stage Products (Phase II)
8. Burns Early Stage Products (Phase I)
9. Burns Preclinical Stage Products
10. Burns Therapeutics Assessment
11. Burns Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Burns Key Companies
14. Burns Key Products
15. Burns Unmet Needs
16 . Burns Market Drivers and Barriers
17. Burns Future Perspectives and Conclusion
18. Burns Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Burns Market https://www.delveinsight.com/report-store/burns-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Burns Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Burns Epidemiology https://www.delveinsight.com/report-store/burns-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Burns Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports Offered By DelveInsight:
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
• Post Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• HiPost Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• Hip Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
• Amblyopia Market: https://www.delveinsight.com/report-store/amblyopia-market
• Type 2 Diabetes Market: https://www.delveinsight.com/report-store/diabetes-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Burns Pipeline 2024: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight by DelveInsight | MediWound, Kaken Pharma, Kerecis, Medline, Mallinckrodt Pharma, Avita Medical, Vericel Corporation, KeraNetics, Integra LifeSciences Corporation here

News-ID: 3888804 • Views:

More Releases from DelveInsight Business Research

Degenerative Disc Disease Clinical Trials 2025: Medication, Pipeline Analysis, EMA, PDMA, FDA Approvals, Treatment Market, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight
Degenerative Disc Disease Clinical Trials 2025: Medication, Pipeline Analysis, E …
(Albany, United States) "Degenerative Disc Disease Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Degenerative Disc Disease Market. As per DelveInsight's assessment, globally, Degenerative Disc Disease pipeline constitutes 15+ key companies continuously working towards developing 15+ Degenerative Disc Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Degenerative Disc Disease
HER2 Positive Breast Cancer Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight
HER2 Positive Breast Cancer Treatment Market 2034: EMA, PDMA, FDA Approval, Clin …
(Albany, USA) DelveInsight's "HER2 Positive Breast Cancer Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the HER2 Positive Breast Cancer, historical and forecasted epidemiology as well as the HER2 Positive Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The HER2 Positive Breast Cancer market is expected to surge due to the disease's increasing prevalence and awareness during
Post-Polycythemia Vera Myelofibrosis Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Treatment Market, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight | Kartos Therapeutics, Inc., Parexel, Constellation Pharmaceuticals, Incyte
Post-Polycythemia Vera Myelofibrosis Clinical Trials 2025: EMA, PDMA, FDA Approv …
(Albany, USA) DelveInsight's "Post-Polycythemia Vera Myelofibrosis Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders-including researchers, healthcare investors, and decision-makers, seeking insights into the evolving Post-Polycythemia Vera Myelofibrosis Therapeutics Market and the breakthroughs shaping its future trajectory. According to DelveInsight,
Knee Osteoarthritis Market to Expand Significantly by 2034, States DelveInsight Report | Paradigm Biopharma, Organogenesis, BioSenic (Bone Therapeutics), Sorrento Therapeutics, Inc., ICM Biotech Australia, Grünenthal GmbH, Akan Biosciences
Knee Osteoarthritis Market to Expand Significantly by 2034, States DelveInsight …
DelveInsight's "Knee Osteoarthritis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Knee Osteoarthritis, historical and forecasted epidemiology as well as the Knee Osteoarthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Knee Osteoarthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Knee Osteoarthritis Market Forecast https://www.delveinsight.com/sample-request/knee-osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the

All 5 Releases


More Releases for Burns

Grow Delivers Robust Loan Qualification Technology to Burns Funding
Grow (https://growfunders.com/), a platform technology company that helps financial services companies and similar entities streamline the loan qualification process, announced today that Burns Funding has become a new client. Burns Funding, a venture debt lender that helps entrepreneurs and investors obtain capital for their existing businesses as well as new ones, needed Grow's Technological platform solution to help it manage the surging demand for its unique product - the Burns Corporate
Bravemark Welcomes Industry Expert Ben Burns as an Advisor
**Miami, Florida - April 17, 2025** - Bravemark, the innovative startup built specifically for brand identity designers, is proud to announce that renowned creative leader and entrepreneur **Ben Burns** has officially joined the company as its first Advisor. With an illustrious career including leadership at *The Futur* alongside Chris Do, creative studio *Blind*, and as founder of the business accelerator *Maker Division*, Burns brings unparalleled expertise to steer Bravemark's strategic vision
Burns Funding Names Rogul Director of Business Development
Burns Funding (www.burnsfunding.com), a venture debt lender that helps entrepreneurs and investors obtain funding for their businesses, has named Daniel "The Dan" Rogul as Director of Business Development. Daniel Rogul, whose past associates credited him with the name of "The Dan" both because of his innate ability to recognize partnership opportunities and close deals, as well as the high standards he has in how he treats people, joins Grace Gillespie, which
Burns Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Burns Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Burns pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Burns Research. Learn more about our innovative pipeline
Steve & Burns: Simplifying Tax Consulting for Small Businesses
Dallas, Texas - Steve & Burns Tax Consulting Services, a leading tax advisory firm, is proud to announce its comprehensive range of tax consulting services [https://steveandburns.com/] specifically tailored to meet the needs of small businesses. As businesses continue to navigate complex tax laws, Steve & Burns offers expert guidance to help companies minimize tax liabilities, optimize tax strategies, and ensure compliance with the latest regulations. Specialized Tax Consulting Services for Small
Rising Burns Cases Raising Skin Replacement and Substitute Demand
Every year, 180,000 people are burned to death, says the World Health Organization (WHO). Moreover, “Non-fatal burn injuries are a leading cause of morbidity.”, in which case victims suffer significant skin damage. Similarly, there are several injuries and infectious diseases, such as necrotizing fasciitis and leprosy, which require skin grafting from one part of the body to another. Earlier, many people, especially in developing countries, would merely get the minimum